Current situation and future development of the biopharmaceutical industry in China: A mixed-method study
Introduction: The biomedical industry has grown significantly both globally and in China; however, there are still challenges. This study aimed at evaluating the biopharmaceutical sector of China, in terms of ability to innovate, current sales volume, investment, and R&D expenditure, as well...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.911165/full |
| _version_ | 1798041923301146624 |
|---|---|
| author | Ruomeng Yang John Alimamy Kabba John Alimamy Kabba John Alimamy Kabba Xuelin Yao Xuelin Yao Xuelin Yao Caijun Yang Caijun Yang Caijun Yang Jie Chang Jie Chang Jie Chang Wenjing Ji Wenjing Ji Wenjing Ji Minghuan Jiang Minghuan Jiang Minghuan Jiang Mingyue Zhao Mingyue Zhao Mingyue Zhao Jun Wen Yu Fang Yu Fang Yu Fang |
| author_facet | Ruomeng Yang John Alimamy Kabba John Alimamy Kabba John Alimamy Kabba Xuelin Yao Xuelin Yao Xuelin Yao Caijun Yang Caijun Yang Caijun Yang Jie Chang Jie Chang Jie Chang Wenjing Ji Wenjing Ji Wenjing Ji Minghuan Jiang Minghuan Jiang Minghuan Jiang Mingyue Zhao Mingyue Zhao Mingyue Zhao Jun Wen Yu Fang Yu Fang Yu Fang |
| author_sort | Ruomeng Yang |
| collection | DOAJ |
| description | Introduction: The biomedical industry has grown significantly both globally and in China; however, there are still challenges. This study aimed at evaluating the biopharmaceutical sector of China, in terms of ability to innovate, current sales volume, investment, and R&D expenditure, as well as providing a case study detailing the progress and challenges of the industry in Shaanxi province.Method: A cross-sectional mixed-method study design was used to generate a comprehensive profile of the nature of biopharmaceutical innovation capacity and development in China by triangulating country-wide survey and interview data from Shaanxi province. Only biopharmaceutical companies that are currently marketing or conducting research and development were eligible for inclusion, and Shaanxi province was selected for conducting the interviews. Categorical and continuous variables were analyzed descriptively. Interviews were thematically analyzed by using NVivo version 12.Results: The analysis includes responses from 77 biopharmaceutical enterprises; the majority (36, 46.8%) are in Eastern China, followed by 26 (33.8%) in Central China. In 2018, the total sales of biological products amounted to 26.28 billion yuan, and in 2019, a slight increase was observed (30.34 billion); the amount doubled in 2020 to about 67.91 billion yuan. The top three biopharmaceutical products on sale in 2020 were Camrelizumab (5.14 billion yuan), human albumin (4.56 billion yuan), and human immunoglobulin for injection (3.78 billion yuan). Expenditure on R&D has also increased; it amounted to 1657.7 million yuan in 2018, which more than doubled in 2019 to 3572.1 million yuan and further increased to 5857.7 million yuan in 2020. Nonetheless, the progress is not uniform across all provinces, as shown from the results from Shaanxi province, because of lack of local government policies that will impact on the funding, incentives, and market share that motivate the producers.Conclusion: China’s biopharmaceutical industry has expand significantly. The increase in sales indicates that there is an increase in demand for biologicals; moreover, R&D funding is increasing. These are key indicators that influence innovation and development. However, the sector’s capacity to innovate and develop needs to be improved, particularly in the western region, where research and production are relatively weak. |
| first_indexed | 2024-04-11T22:28:19Z |
| format | Article |
| id | doaj.art-42426ce5c82143b3bd5106d7e792afa3 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-11T22:28:19Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-42426ce5c82143b3bd5106d7e792afa32022-12-22T03:59:36ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-08-011310.3389/fphar.2022.911165911165Current situation and future development of the biopharmaceutical industry in China: A mixed-method studyRuomeng Yang0John Alimamy Kabba1John Alimamy Kabba2John Alimamy Kabba3Xuelin Yao4Xuelin Yao5Xuelin Yao6Caijun Yang7Caijun Yang8Caijun Yang9Jie Chang10Jie Chang11Jie Chang12Wenjing Ji13Wenjing Ji14Wenjing Ji15Minghuan Jiang16Minghuan Jiang17Minghuan Jiang18Mingyue Zhao19Mingyue Zhao20Mingyue Zhao21Jun Wen22Yu Fang23Yu Fang24Yu Fang25Department of Industrial Economics and Trade, School of Economics and Finance, Xi’an Jiaotong University, Xi’an, ChinaDepartment of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi’an Jiaotong University, Xi’an, ChinaCenter for Drug Safety and Policy Research, Xi’an Jiaotong University, Xi’an, ChinaShaanxi Centre for Health Reform and Development Research, Xi’an, ChinaDepartment of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi’an Jiaotong University, Xi’an, ChinaCenter for Drug Safety and Policy Research, Xi’an Jiaotong University, Xi’an, ChinaShaanxi Centre for Health Reform and Development Research, Xi’an, ChinaDepartment of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi’an Jiaotong University, Xi’an, ChinaCenter for Drug Safety and Policy Research, Xi’an Jiaotong University, Xi’an, ChinaShaanxi Centre for Health Reform and Development Research, Xi’an, ChinaDepartment of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi’an Jiaotong University, Xi’an, ChinaCenter for Drug Safety and Policy Research, Xi’an Jiaotong University, Xi’an, ChinaShaanxi Centre for Health Reform and Development Research, Xi’an, ChinaDepartment of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi’an Jiaotong University, Xi’an, ChinaCenter for Drug Safety and Policy Research, Xi’an Jiaotong University, Xi’an, ChinaShaanxi Centre for Health Reform and Development Research, Xi’an, ChinaDepartment of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi’an Jiaotong University, Xi’an, ChinaCenter for Drug Safety and Policy Research, Xi’an Jiaotong University, Xi’an, ChinaShaanxi Centre for Health Reform and Development Research, Xi’an, ChinaDepartment of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi’an Jiaotong University, Xi’an, ChinaCenter for Drug Safety and Policy Research, Xi’an Jiaotong University, Xi’an, ChinaShaanxi Centre for Health Reform and Development Research, Xi’an, ChinaDepartment of Industrial Economics and Trade, School of Economics and Finance, Xi’an Jiaotong University, Xi’an, ChinaDepartment of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi’an Jiaotong University, Xi’an, ChinaCenter for Drug Safety and Policy Research, Xi’an Jiaotong University, Xi’an, ChinaShaanxi Centre for Health Reform and Development Research, Xi’an, ChinaIntroduction: The biomedical industry has grown significantly both globally and in China; however, there are still challenges. This study aimed at evaluating the biopharmaceutical sector of China, in terms of ability to innovate, current sales volume, investment, and R&D expenditure, as well as providing a case study detailing the progress and challenges of the industry in Shaanxi province.Method: A cross-sectional mixed-method study design was used to generate a comprehensive profile of the nature of biopharmaceutical innovation capacity and development in China by triangulating country-wide survey and interview data from Shaanxi province. Only biopharmaceutical companies that are currently marketing or conducting research and development were eligible for inclusion, and Shaanxi province was selected for conducting the interviews. Categorical and continuous variables were analyzed descriptively. Interviews were thematically analyzed by using NVivo version 12.Results: The analysis includes responses from 77 biopharmaceutical enterprises; the majority (36, 46.8%) are in Eastern China, followed by 26 (33.8%) in Central China. In 2018, the total sales of biological products amounted to 26.28 billion yuan, and in 2019, a slight increase was observed (30.34 billion); the amount doubled in 2020 to about 67.91 billion yuan. The top three biopharmaceutical products on sale in 2020 were Camrelizumab (5.14 billion yuan), human albumin (4.56 billion yuan), and human immunoglobulin for injection (3.78 billion yuan). Expenditure on R&D has also increased; it amounted to 1657.7 million yuan in 2018, which more than doubled in 2019 to 3572.1 million yuan and further increased to 5857.7 million yuan in 2020. Nonetheless, the progress is not uniform across all provinces, as shown from the results from Shaanxi province, because of lack of local government policies that will impact on the funding, incentives, and market share that motivate the producers.Conclusion: China’s biopharmaceutical industry has expand significantly. The increase in sales indicates that there is an increase in demand for biologicals; moreover, R&D funding is increasing. These are key indicators that influence innovation and development. However, the sector’s capacity to innovate and develop needs to be improved, particularly in the western region, where research and production are relatively weak.https://www.frontiersin.org/articles/10.3389/fphar.2022.911165/fullbiopharmaceuticalbiotechnologybiosimilarsChinainnovationbiological medicine |
| spellingShingle | Ruomeng Yang John Alimamy Kabba John Alimamy Kabba John Alimamy Kabba Xuelin Yao Xuelin Yao Xuelin Yao Caijun Yang Caijun Yang Caijun Yang Jie Chang Jie Chang Jie Chang Wenjing Ji Wenjing Ji Wenjing Ji Minghuan Jiang Minghuan Jiang Minghuan Jiang Mingyue Zhao Mingyue Zhao Mingyue Zhao Jun Wen Yu Fang Yu Fang Yu Fang Current situation and future development of the biopharmaceutical industry in China: A mixed-method study Frontiers in Pharmacology biopharmaceutical biotechnology biosimilars China innovation biological medicine |
| title | Current situation and future development of the biopharmaceutical industry in China: A mixed-method study |
| title_full | Current situation and future development of the biopharmaceutical industry in China: A mixed-method study |
| title_fullStr | Current situation and future development of the biopharmaceutical industry in China: A mixed-method study |
| title_full_unstemmed | Current situation and future development of the biopharmaceutical industry in China: A mixed-method study |
| title_short | Current situation and future development of the biopharmaceutical industry in China: A mixed-method study |
| title_sort | current situation and future development of the biopharmaceutical industry in china a mixed method study |
| topic | biopharmaceutical biotechnology biosimilars China innovation biological medicine |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.911165/full |
| work_keys_str_mv | AT ruomengyang currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT johnalimamykabba currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT johnalimamykabba currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT johnalimamykabba currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT xuelinyao currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT xuelinyao currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT xuelinyao currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT caijunyang currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT caijunyang currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT caijunyang currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT jiechang currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT jiechang currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT jiechang currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT wenjingji currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT wenjingji currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT wenjingji currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT minghuanjiang currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT minghuanjiang currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT minghuanjiang currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT mingyuezhao currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT mingyuezhao currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT mingyuezhao currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT junwen currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT yufang currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT yufang currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy AT yufang currentsituationandfuturedevelopmentofthebiopharmaceuticalindustryinchinaamixedmethodstudy |